{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:46:09Z","timestamp":1778510769468,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111\u20132320-B-039\u2013049"],"award-info":[{"award-number":["111\u20132320-B-039\u2013049"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["CMU111-MF-23"],"award-info":[{"award-number":["CMU111-MF-23"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR- 108\u2013022"],"award-info":[{"award-number":["DMR- 108\u2013022"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jgar.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T22:05:17Z","timestamp":1686866717000},"page":"46-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials"],"prefix":"10.1016","volume":"34","author":[{"given":"Meng-Hsuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5459-5378","authenticated-orcid":false,"given":"Yi-Cheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Yun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-6699","authenticated-orcid":false,"given":"Chi-Kang","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-5558","authenticated-orcid":false,"given":"Wei-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-2898","authenticated-orcid":false,"given":"Yu-Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-4834","authenticated-orcid":false,"given":"Chin-Chuan","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jgar.2023.05.011_bib0001","first-page":"65","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2023.05.011_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40121-015-0081-y","article-title":"Considerations about antimicrobial stewardship in settings with epidemic extended-spectrum \u03b2-lactamase-producing or carbapenem-resistant Enterobacteriaceae","volume":"4","author":"Viale","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2023.05.011_bib0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13054-016-1197-5","article-title":"Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?","volume":"20","author":"Bassetti","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2023.05.011_bib0004","series-title":"Clinicians: information about CRE","year":"2019"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.011_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/0885066615619895","article-title":"Antimicrobial resistance in the intensive care unit: a focus on Gram-negative bacterial infections","volume":"32","author":"MacVane","year":"2017","journal-title":"J Intensive Care Med"},{"issue":"10","key":"10.1016\/j.jgar.2023.05.011_bib0006","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/phar.1636","article-title":"Infections caused by resistant Gram-negative bacteria: epidemiology and management","volume":"35","author":"Kaye","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.jgar.2023.05.011_bib0007","doi-asserted-by":"crossref","first-page":"235","DOI":"10.15585\/mmwr.mm6509e1","article-title":"Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014","volume":"65","author":"Weiner","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/mdr.2015.0220","article-title":"Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options","volume":"22","author":"Cerceo","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2023.05.011_bib0009","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","year":"2017"},{"issue":"3","key":"10.1016\/j.jgar.2023.05.011_bib0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/sur.2006.100","article-title":"Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections","volume":"9","author":"Edelsberg","year":"2008","journal-title":"Surg Infect (Larchmt)"},{"issue":"3","key":"10.1016\/j.jgar.2023.05.011_bib0011","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"10.1016\/j.jgar.2023.05.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jgar.2023.05.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1089\/mdr.2019.0298","article-title":"Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City","volume":"26","author":"Iregui","year":"2020","journal-title":"Microb Drug Resist"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"in vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jgar.2023.05.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"39","key":"10.1016\/j.jgar.2023.05.011_bib0016","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.011_bib0017","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jgar.2023.05.011_bib0018","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0019","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","article-title":"A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens","volume":"46","author":"Bush","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.jgar.2023.05.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jgar.2023.05.011_bib0021","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs Class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02313-19","article-title":"meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.011_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/AAC.00912-09","article-title":"In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance","volume":"54","author":"Bulik","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijantimicag.2009.03.021","article-title":"Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates","volume":"34","author":"Livermore","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jgar.2023.05.011_bib0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.00834-09","article-title":"Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains","volume":"54","author":"Juan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.011_bib0026","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/AAC.01752-10","article-title":"In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms","volume":"56","author":"Bulik","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0027","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol Chem"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0028","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jgar.2023.05.011_bib0029","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jgar.2023.05.011_bib0030","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jgar.2023.05.011_bib0031","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jgar.2023.05.011_bib0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jgar.2023.05.011_bib0033","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1016\/j.jgar.2023.05.011_bib0034","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"26","key":"10.1016\/j.jgar.2023.05.011_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess"},{"issue":"7521","key":"10.1016\/j.jgar.2023.05.011_bib0036","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.jgar.2023.05.011_bib0037","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"issue":"24","key":"10.1016\/j.jgar.2023.05.011_bib0038","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"issue":"16","key":"10.1016\/j.jgar.2023.05.011_bib0039","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.jgar.2023.05.011_bib0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2023.05.011_bib0041","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2023.05.011_bib0042","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jgar.2023.05.011_bib0043","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/biom.12762","article-title":"A matrix-based method of moments for fitting multivariate network meta-analysis models with multiple outcomes and random inconsistency effects","volume":"74","author":"Jackson","year":"2018","journal-title":"Biometrics"},{"issue":"29","key":"10.1016\/j.jgar.2023.05.011_bib0044","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/sim.5453","article-title":"Quantifying the impact of between-study heterogeneity in multivariate meta-analyses","volume":"31","author":"Jackson","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2023.05.011_bib0045","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"7\u20138","key":"10.1016\/j.jgar.2023.05.011_bib0046","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jgar.2023.05.011_bib0047","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res Synth Methods"},{"issue":"7","key":"10.1016\/j.jgar.2023.05.011_bib0048","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"R\u00e9a-Neto","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jgar.2023.05.011_bib0049","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.jgar.2023.05.011_bib0050","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2023.05.011_bib0051","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijsu.2005.03.011","article-title":"Tigecycline is efficacious in the treatment of complicated intra-abdominal infections","volume":"3","author":"Fomin","year":"2005","journal-title":"Int J Surg"},{"key":"10.1016\/j.jgar.2023.05.011_bib0052","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections","volume":"5:","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0053","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2023.05.011_bib0054","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-10-217","article-title":"Efficacy and safety of tigecycline monotherapy vs. imipenem\/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial","volume":"10","author":"Chen","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0055","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jgar.2023.05.011_bib0056","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2023.05.011_bib0057","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jgar.2023.05.011_bib0058","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jgar.2023.05.011_bib0059","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.05.011_bib0061","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2147\/TCRM.S171821","article-title":"A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem\/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China","volume":"14","author":"Chen","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.jgar.2023.05.011_bib0062","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1015-9584(09)60039-7","article-title":"Randomized comparison of piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of patients with intra-abdominal infection","volume":"27","author":"Erasmo","year":"2004","journal-title":"Asian J Surg"},{"issue":"12","key":"10.1016\/j.jgar.2023.05.011_bib0063","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"9981","key":"10.1016\/j.jgar.2023.05.011_bib0064","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jgar.2023.05.011_bib0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jgar.2023.05.011_bib0066","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jgar.2023.05.011_bib0067","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2023.05.011_bib0068","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7164\/antibiotics.37.394","article-title":"Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli","volume":"37","author":"Hashizume","year":"1984","journal-title":"J Antibiot (Tokyo)"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2023.05.011_bib0069","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2007.01860.x","article-title":"Extended-spectrum beta-lactamases and the permeability barrier","volume":"14","author":"Mart\u00ednez-Mart\u00ednez","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.jgar.2023.05.011_bib0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2013.10.021","article-title":"Prolonging \u03b2-lactam infusion: a review of the rationale and evidence, and guidance for implementation","volume":"43","author":"MacVane","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.jgar.2023.05.011_bib0071","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.chest.2020.10.039","article-title":"carbapenem antibiotics for the empiric treatment of nosocomial pneumonia: a systematic review and meta-analysis","volume":"159","author":"Howatt","year":"2021","journal-title":"Chest"},{"issue":"40","key":"10.1016\/j.jgar.2023.05.011_bib0072","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017436","article-title":"Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: a Bayesian network meta-analysis of randomized clinical trials","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.jgar.2023.05.011_bib0073","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018769","article-title":"Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection: a systematic review and network meta-analysis","volume":"99","author":"Tan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2023.05.011_bib0074","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13017-017-0132-7","article-title":"Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J Emerg Surg"},{"issue":"12","key":"10.1016\/j.jgar.2023.05.011_bib0075","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","article-title":"High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia","volume":"184","author":"Chung","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jgar.2023.05.011_bib0076","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jgar.2023.05.011_bib0077","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:16Z","timestamp":1761991276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":77,"alternative-id":["S2213716523000899"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.05.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}